{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T15:00:45Z","timestamp":1789138845968,"version":"build-2803163510"},"reference-count":121,"publisher":"Bentham Science Publishers Ltd.","issue":"36","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMC"],"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Hyperuricemia belongs to metabolic syndromes where increased uric\nacid levels are identified in the blood serum. Such a syndrome could be responsible for kidney\nstone formation, gout, hypertension, and chronic kidney diseases. It has been reported\nthat cardiovascular risks have been linked with hyperuricemia. Gout is of the most frequent\nmanifestations due to hyperuricemia; its management involves various pharmacological available\noptions and dietary changes. Throughout the literature, various dosage forms are studied\nas alternative options to the present drug delivery systems.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To update and summarize the current information for gout and hyperuricemia management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Authors have performed a thorough literature research from 2010-2023 using keywords\nsuch as hyperuricemia, gout, diagnosis, guidelines, drug delivery and clinical trials.\nThe databases used were PubMed, ScienceDirect. According to our inclusion criteria, all\nstudies which include the previous terms, as well as drugs or other molecules that can be applied\nfor gout and\/or hyperuricemia management, were added.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>In this article, authors have summarized the pathogenesis, diagnosis and updated\nguidelines for gout and hyperuricemia management. Moreover, the authors have reviewed\nand discussed current drug delivery systems found in the literature, including drugs targeting\nthe above disorders. Finally, the available clinical trials assessing the efficacy of newer drugs\nor combinations of the past ones, are being discussed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>The available drugs and dosage forms are limited, and therefore, scientific society\nshould focus on the development of more efficient drug delivery systems for hyperuricemia\nand gout management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/0929867331666230809143758","type":"journal-article","created":{"date-parts":[[2023,8,10]],"date-time":"2023-08-10T00:33:16Z","timestamp":1691627596000},"page":"5856-5883","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["An Updated Review For Hyperuricemia and Gout Management; Special Focus on the Available Drug Delivery Systems and Clinical Trials"],"prefix":"10.2174","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7020-3060","authenticated-orcid":true,"given":"Ioannis D.","family":"Karantas","sequence":"first","affiliation":[{"name":"Apostolos Loukas Medical Centre, Nicosia, Cyprus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9111-8615","authenticated-orcid":true,"given":"Androulla N.","family":"Miliotou","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, KES College, Nicosia,\nCyprus"},{"name":"Department of Life and Health Sciences, Faculty of Pharmacy, University of Nicosia, Nicosia, Cyprus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7256-3230","authenticated-orcid":true,"given":"Panoraia I.","family":"Siafaka","sequence":"additional","affiliation":[{"name":"Department of Life Sciences, Faculty of Pharmacy, School of Sciences, European University Cyprus, Nicosia, Cyprus"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1186\/1471-2369-14-164","volume":"14","author":"Gustafsson D.","year":"2013","unstructured":"Gustafsson D.; Unwin R.; The pathophysiology of hyperuricaemia and its possible relationship to cardiovascular disease, morbidity and mortality. BMC Nephrol  2013,14(1),164","journal-title":"BMC Nephrol"},{"key":"ref=2","first-page":"1295","volume":"18","author":"Desideri G.","year":"2014","unstructured":"Desideri G.; Castaldo G.; Lombardi A.; Mussap M.; Testa A.; Pontremoli R.; Punzi L.; Borghi C.; Is it time to revise the normal range of serum uric acid levels? Eur Rev Med Pharmacol Sci  2014,18(9),1295-1306","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"ref=3","author":"George C.","year":"2022","unstructured":"George C.; Minter D.A.; Hyperuricemia. StatPearls  2022","journal-title":"StatPearls"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"312","DOI":"10.5114\/reum.2020.100140","volume":"58","author":"Skoczy\u0144ska M.","year":"2020","unstructured":"Skoczy\u0144ska M.; Chowaniec M.; Szymczak A.; Langner-Hetma\u0144czuk A.; Maci\u0105\u017cek-Chyra B.; Wiland P.; Pathophysiology of hyperuricemia and its clinical significance \u2013 a narrative review. Reumatologia  2020,58(5),312-323","journal-title":"Reumatologia"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1097\/BOR.0000000000000779","volume":"33","author":"Yokose C.","year":"2021","unstructured":"Yokose C.; McCormick N.; Choi H.K.; The role of diet in hyperuricemia and gout. Curr Opin Rheumatol  2021,33(2),135-144","journal-title":"Curr Opin Rheumatol"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"9221","DOI":"10.3390\/ijms22179221","volume":"22","author":"Yanai H.","year":"2021","unstructured":"Yanai H.; Adachi H.; Hakoshima M.; Katsuyama H.; Molecular biological and clinical understanding of the pathophysiology and treatments of hyperuricemia and its association with metabolic syndrome, cardiovascular diseases and chronic kidney disease. Int J Mol Sci  2021,22(17),9221","journal-title":"Int J Mol Sci"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"428","DOI":"10.3889\/oamjms.2021.7100","volume":"9","author":"Mahadita G.W.","year":"2021","unstructured":"Mahadita G.W.; Suwitra K.; The role of hyperuricemia in the pathogenesis and progressivity of chronic kidney disease. Open Access Maced J Med Sci  2021,9,428-435","journal-title":"Open Access Maced J Med Sci"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"160","DOI":"10.3389\/fmed.2018.00160","volume":"5","author":"Benn C.L.","year":"2018","unstructured":"Benn C.L.; Dua P.; Gurrell R.; Loudon P.; Pike A.; Storer R.I.; Vangjeli C.; Physiology of hyperuricemia and urate-lowering treatments. Front Med  2018,5,160","journal-title":"Front Med"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"582680","DOI":"10.3389\/fphar.2020.582680","volume":"11","author":"Yu W.","year":"2020","unstructured":"Yu W.; Cheng J.D.; Uric acid and cardiovascular disease: an update from molecular mechanism to clinical perspective. Front Pharmacol  2020,11,582680","journal-title":"Front Pharmacol"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"2501","DOI":"10.12659\/MSM.899852","volume":"22","author":"Chen C.","year":"2016","unstructured":"Chen C.; L\u00fc J.M.; Yao Q.; Hyperuricemia-related diseases and xanthine oxidoreductase (XOR) inhibitors: An overview. Med Sci Monit  2016,22,2501-2512","journal-title":"Med Sci Monit"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1038\/s41584-020-0441-1","volume":"16","author":"Dehlin M.","year":"2020","unstructured":"Dehlin M.; Jacobsson L.; Roddy E.; Global epidemiology of gout: Prevalence, incidence, treatment patterns and risk factors. Nat Rev Rheumatol  2020,16(7),380-390","journal-title":"Nat Rev Rheumatol"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1093\/qjmed\/hcr242","volume":"105","author":"Suresh E.","year":"2012","unstructured":"Suresh E.; Das P.; Recent advances in management of gout. QJM  2012,105(5),407-417","journal-title":"QJM"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"23","DOI":"10.2147\/VHRM.S115080","volume":"13","author":"Bove M.","year":"2017","unstructured":"Bove M.; Cicero A.F.G.; Veronesi M.; Borghi C.; An evidence-based review on urate-lowering treatments: Implications for optimal treatment of chronic hyperuricemia. Vasc Health Risk Manag  2017,13,23-28","journal-title":"Vasc Health Risk Manag"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.jddst.2017.04.020","volume":"39","author":"Singh S.","year":"2017","unstructured":"Singh S.; Parashar P.; Kanoujia J.; Singh I.; Saha S.; Saraf S.A.; Transdermal potential and anti-gout efficacy of Febuxostat from niosomal gel. J Drug Deliv Sci Technol  2017,39,348-361","journal-title":"J Drug Deliv Sci Technol"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1016\/j.ijbiomac.2022.04.116","volume":"209","author":"Kim H.S.","year":"2022","unstructured":"Kim H.S.; Lee C.M.; Yun Y.H.; Kim Y.S.; Yoon S.; Synthesis and drug release properties of melanin added functional allopurinol incorporated starch-based biomaterials. Int J Biol Macromol  2022,209,1477-1485","journal-title":"Int J Biol Macromol"},{"key":"ref=16","first-page":"82","volume":"35","author":"Avena-Woods C.","year":"2010","unstructured":"Avena-Woods C.; Hilas O.; Febuxostat (Uloric), a new treatment option for gout. PandT  2010,35(2),82-85","journal-title":"PandT"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1136\/annrheumdis-2012-201795","volume":"72","author":"Becker M.A.","year":"2013","unstructured":"Becker M.A.; Baraf H.S.B.; Yood R.A.; Dillon A.; V\u00e1zquez-Mellado J.; Ottery F.D.; Khanna D.; Sundy J.S.; Long-term safety of pegloticase in chronic gout refractory to conventional treatment. Ann Rheum Dis  2013,72(9),1469-1474","journal-title":"Ann Rheum Dis"},{"key":"ref=18","unstructured":"FDA-Biologic License Application (BLA): 125293 FDA Available from:  https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=BasicSearch.process (Accessed on: 2023-03-02).","journal-title":"FDA-Biologic License Application (BLA): 125293"},{"key":"ref=19","unstructured":"FDA-New Drug Application (NDA): 207988 FDA Available from:  https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.processandApplNo=207988 (Accessed on: 2023-03-02).","journal-title":"FDA-New Drug Application (NDA): 207988"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"12394","DOI":"10.3390\/ijms222212394","volume":"22","author":"Kimura Y.","year":"2021","unstructured":"Kimura Y.; Tsukui D.; Kono H.; Uric acid in inflammation and the pathogenesis of atherosclerosis. Int J Mol Sci  2021,22(22),12394","journal-title":"Int J Mol Sci"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.3904\/kjim.2020.410","volume":"35","author":"Park J.H.","year":"2020","unstructured":"Park J.H.; Jo Y.I.; Lee J.H.; Renal effects of uric acid: Hyperuricemia and hypouricemia. Korean J Intern Med  2020,35(6),1291-1304","journal-title":"Korean J Intern Med"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1007\/s11926-016-0594-8","volume":"18","author":"Vargas-Santos A.B.","year":"2016","unstructured":"Vargas-Santos A.B.; Taylor W.J.; Neogi T.; Gout classification criteria: Update and implications. Curr Rheumatol Rep  2016,18(7),46","journal-title":"Curr Rheumatol Rep"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"6678","DOI":"10.3390\/ijms22136678","volume":"22","author":"Eckenstaler R.","year":"2021","unstructured":"Eckenstaler R.; Benndorf R.A.; The role of ABCG2 in the pathogenesis of primary hyperuricemia and gout\u2014an update. Int J Mol Sci  2021,22(13),6678","journal-title":"Int J Mol Sci"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/1750-1172-2-48","volume":"2","author":"Torres R.J.","year":"2007","unstructured":"Torres R.J.; Puig J.G.; Hypoxanthine-guanine phosophoribosyltransferase (HPRT) deficiency: Lesch-Nyhan syndrome. Orphanet J Rare Dis  2007,2(1),48","journal-title":"Orphanet J Rare Dis"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1159\/000509934","volume":"45","author":"Matuszkiewicz-Rowinska J.","year":"2020","unstructured":"Matuszkiewicz-Rowinska J.; Malyszko J.; Prevention and treatment of tumor lysis syndrome in the era of onco-nephrology progress. Kidney Blood Press Res  2020,45(5),645-660","journal-title":"Kidney Blood Press Res"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1007\/s11926-013-0400-9","volume":"16","author":"Martillo M.A.","year":"2014","unstructured":"Martillo M.A.; Nazzal L.; Crittenden D.B.; The crystallization of monosodium urate. Curr Rheumatol Rep  2014,16(2),400","journal-title":"Curr Rheumatol Rep"},{"key":"ref=27","first-page":"13","volume":"63","author":"Singh H.","year":"2008","unstructured":"Singh H.; Torralba K.D.; Therapeutic challenges in the management of gout in the elderly. Geriatrics  2008,63(7),13-18, 20","journal-title":"Geriatrics"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"e026677","DOI":"10.1136\/bmjopen-2018-026677","volume":"9","author":"Li Q.","year":"2019","unstructured":"Li Q.; Li X.; Wang J.; Liu H.; Kwong J.S.W.; Chen H.; Li L.; Chung S.C.; Shah A.; Chen Y.; An Z.; Sun X.; Hemingway H.; Tian H.; Li S.; Diagnosis and treatment for hyperuricemia and gout: A systematic review of clinical practice guidelines and consensus statements. BMJ Open  2019,9(8),e026677","journal-title":"BMJ Open"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"400","DOI":"10.7861\/clinmedicine.13-4-400","volume":"13","author":"Roddy E.","year":"2013","unstructured":"Roddy E.; Doherty M.; Treatment of hyperuricaemia and gout. Clin Med  2013,13(4),400-403","journal-title":"Clin Med"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1016\/j.clinthera.2014.07.017","volume":"36","author":"Dalbeth N.","year":"2014","unstructured":"Dalbeth N.; Lauterio T.J.; Wolfe H.R.; Mechanism of action of colchicine in the treatment of gout. Clin Ther  2014,36(10),1465-1479","journal-title":"Clin Ther"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1136\/annrheumdis-2022-222199","volume":"81","author":"Lu J.","year":"2022","unstructured":"Lu J.; He Y.; Terkeltaub R.; Sun M.; Ran Z.; Xu X.; Wang C.; Li X.; Hu S.; Xue X.; Yan F.; Zhang H.; Yin H.; Shi Y.; Dalbeth N.; Li C.; Colchicine prophylaxis is associated with fewer gout flares after COVID-19 vaccination. Ann Rheum Dis  2022,81(8),1189-1193","journal-title":"Ann Rheum Dis"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"109977","DOI":"10.1016\/j.intimp.2023.109977","volume":"117","author":"Tao H.","year":"2023","unstructured":"Tao H.; Mo Y.; Liu W.; Wang H.; A review on gout: Looking back and looking ahead. Int Immunopharmacol  2023,117,109977","journal-title":"Int Immunopharmacol"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1002\/acr.24180","volume":"72","author":"FitzGerald J.D.","year":"2020","unstructured":"FitzGerald J.D.; Dalbeth N.; Mikuls T.; Brignardello-Petersen R.; Guyatt G.; Abeles A.M.; Gelber A.C.; Harrold L.R.; Khanna D.; King C.; Levy G.; Libbey C.; Mount D.; Pillinger M.H.; Rosenthal A.; Singh J.A.; Sims J.E.; Smith B.J.; Wenger N.S.; Bae S.S.; Danve A.; Khanna P.P.; Kim S.C.; Lenert A.; Poon S.; Qasim A.; Sehra S.T.; Sharma T.S.K.; Toprover M.; Turgunbaev M.; Zeng L.; Zhang M.A.; Turner A.S.; Neogi T.; 2020 American college of rheumatology guideline for the management of gout. Arthritis Care Res  2020,72(6),744-760","journal-title":"Arthritis Care Res"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1016\/B978-0-323-09138-1.00189-3","author":"Terkeltaub R.","year":"2015","unstructured":"Terkeltaub R.; Management of gout and hyperuricemia. Rheumatology  2015,1575-1582","journal-title":"Rheumatology"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1186\/s13075-018-1755-0","volume":"20","author":"Stamp L.K.","year":"2018","unstructured":"Stamp L.K.; Chapman P.T.; Barclay M.L.; Horne A.; Frampton C.; Tan P.; Drake J.; Dalbeth N.; How much allopurinol does it take to get to target urate? Comparison of actual dose with creatinine clearance-based dose. Arthritis Res Ther  2018,20(1),255","journal-title":"Arthritis Res Ther"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1002\/art.40685","volume":"71","author":"Saag K.G.","year":"2019","unstructured":"Saag K.G.; Becker M.A.; Whelton A.; Hunt B.; Castillo M.; Kisfalvi K.; Gunawardhana L.; Efficacy and safety of febuxostat extended and immediate release in patients with gout and renal impairment: A phase  placebo-controlled study. Arthritis Rheumatol  2019,71(1),143-153","journal-title":"Arthritis Rheumatol"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s42358-019-0080-x","volume":"59","author":"Azevedo V.F.","year":"2019","unstructured":"Azevedo V.F.; Kos I.A.; Vargas-Santos A.B.; da Rocha C.P.G.; dos Santos P.E.; Benzbromarone in the treatment of gout. Adv Rheumatol  2019,59(1),37","journal-title":"Adv Rheumatol"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"114682","DOI":"10.1016\/j.ejmech.2022.114682","volume":"242","author":"Zhao Z.","year":"2022","unstructured":"Zhao Z.; Liu J.; Yuan L.; Yang Z.; Kuang P.; Liao H.; Luo J.; Feng H.; Zheng F.; Chen Y.; Wu T.; Guo J.; Cao Y.; Yang Y.; Lin C.; Zhang Q.; Chen J.; Pang J.; Discovery of novel benzbromarone analogs with improved pharmacokinetics and benign toxicity profiles as antihyperuricemic agents. Eur J Med Chem  2022,242,114682","journal-title":"Eur J Med Chem"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.2174\/1381612828666220411104128","volume":"28","author":"Okur N.\u00dc.","year":"2022","unstructured":"Okur N.\u00dc.; Siafaka P.I.; Polat D.\u00c7.; Karada\u011f A.E.; K\u00f6pr\u00fcl\u00fc R.E.P.; Karantas I.D.; Mutlu G.; \u00c7a\u011flar E.\u015e.; Okur M.E.; Phytochemical compounds loaded to nanocarriers as potential therapeutic substances for Alzheimer\u2019s disease-could they be effective? Curr Pharm Des  2022,28(30),2437-2460","journal-title":"Curr Pharm Des"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"289","DOI":"10.3389\/fphar.2020.00289","volume":"11","author":"Rahmi E.P.","year":"2020","unstructured":"Rahmi E.P.; Kumolosasi E.; Jalil J.; Husain K.; Buang F.; Abd Razak A.F.; Jamal J.A.; Anti-hyperuricemic and anti-inflammatory effects of Marantodes pumilum as potential treatment for gout. Front Pharmacol  2020,11,289","journal-title":"Front Pharmacol"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2019\/2969364","volume":"2019","author":"Wu Z.","year":"2019","unstructured":"Wu Z.; Xue Q.; Zhao Z.; Zhou P.; Zhou Q.; Zhang Z.; Deng J.; Yang K.; Fan H.; Wang Y.; Wang Z.; Suppressive effect of huzhentongfeng on experimental gouty arthritis: An in vivo and in vitro study. Evid Based Complement Alternat Med  2019,2019,1-15","journal-title":"Evid Based Complement Alternat Med"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1080\/10408398.2010.508568","volume":"52","author":"Ye N.S.","year":"2012","unstructured":"Ye N.S.; A minireview of analytical methods for the geographical origin analysis of teas (Camellia sinensis). Crit Rev Food Sci Nutr  2012,52(9),775-780","journal-title":"Crit Rev Food Sci Nutr"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1080\/13880209.2017.1377736","volume":"55","author":"Zhu C.","year":"2017","unstructured":"Zhu C.; Tai L.L.; Wan X.; Li D.; Zhao Y.Q.; Xu Y.; Comparative effects of green and black tea extracts on lowering serum uric acid in hyperuricemic mice. Pharm Biol  2017,55(1),2123-2128","journal-title":"Pharm Biol"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"7595","DOI":"10.3390\/ijms23147595","volume":"23","author":"Shi M.","year":"2022","unstructured":"Shi M.; Lu Y.; Wu J.; Zheng Z.; Lv C.; Ye J.; Qin S.; Zeng C.; Beneficial effects of theaflavins on metabolic syndrome: From molecular evidence to gut microbiome. Int J Mol Sci  2022,23(14),7595","journal-title":"Int J Mol Sci"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/10408398.2022.2040417","volume":"3","author":"Chen Y.","year":"2022","unstructured":"Chen Y.; Luo L.; Hu S.; Gan R.; Zeng L.; The chemistry, processing, and preclinical anti-hyperuricemia potential of tea: a comprehensive review. Crit Rev Food Sci Nutr  2022,3,1-26","journal-title":"Crit Rev Food Sci Nutr"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"115122","DOI":"10.1016\/j.taap.2020.115122","volume":"402","author":"Afify H.","year":"2020","unstructured":"Afify H.; Abo-Youssef A.M.; Abdel-Rahman H.M.; Allam S.; Azouz A.A.; The modulatory effects of cinnamaldehyde on uric acid level and IL-6\/JAK1\/STAT3 signaling as a promising therapeutic strategy against benign prostatic hyperplasia. Toxicol Appl Pharmacol  2020,402,115122","journal-title":"Toxicol Appl Pharmacol"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/j.phymed.2008.06.002","volume":"15","author":"Wang S.Y.","year":"2008","unstructured":"Wang S.Y.; Yang C.W.; Liao J.W.; Zhen W.W.; Chu F.H.; Chang S.T.; Essential oil from leaves of Cinnamomum osmophloeum acts as a xanthine oxidase inhibitor and reduces the serum uric acid levels in oxonate-induced mice. Phytomedicine  2008,15(11),940-945","journal-title":"Phytomedicine"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"173490","DOI":"10.1016\/j.ejphar.2020.173490","volume":"888","author":"Li Q.","year":"2020","unstructured":"Li Q.; Lin H.; Niu Y.; Liu Y.; Wang Z.; Song L.; Gao L.; Li L.; Mangiferin promotes intestinal elimination of uric acid by modulating intestinal transporters. Eur J Pharmacol  2020,888,173490","journal-title":"Eur J Pharmacol"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.apsb.2017.05.004","volume":"8","author":"Qin Z.","year":"2018","unstructured":"Qin Z.; Wang S.; Lin Y.; Zhao Y.; Yang S.; Song J.; Xie T.; Tian J.; Wu S.; Du G.; Antihyperuricemic effect of mangiferin aglycon derivative J99745 by inhibiting xanthine oxidase activity and urate transporter 1 expression in mice. Acta Pharm Sin B  2018,8(2),306-315","journal-title":"Acta Pharm Sin B"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.ijbiomac.2022.05.188","volume":"213","author":"Li X.","year":"2022","unstructured":"Li X.; Jin W.; Zhang W.; Zheng G.; The inhibitory kinetics and mechanism of quercetin-3-O-rhamnoside and chlorogenic acid derived from Smilax china L. EtOAc fraction on xanthine oxidase. Int J Biol Macromol  2022,213,447-455","journal-title":"Int J Biol Macromol"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.jep.2015.01.012","volume":"162","author":"Wu X.H.","year":"2015","unstructured":"Wu X.H.; Wang C.Z.; Wang S.Q.; Mi C.; He Y.; Zhang J.; Zhang Y.W.; Anderson S.; Yuan C.S.; Anti-hyperuricemia effects of allopurinol are improved by Smilax riparia, a traditional Chinese herbal medicine. J Ethnopharmacol  2015,162,362-368","journal-title":"J Ethnopharmacol"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"111777","DOI":"10.1016\/j.jep.2019.03.004","volume":"238","author":"Huang L.","year":"2019","unstructured":"Huang L.; Deng J.; Chen G.; Zhou M.; Liang J.; Yan B.; Shu J.; Liang Y.; Huang H.; The anti-hyperuricemic effect of four astilbin stereoisomers in Smilax glabra on hyperuricemic mice. J Ethnopharmacol  2019,238,111777","journal-title":"J Ethnopharmacol"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.jep.2014.09.034","volume":"157","author":"Wu X.H.","year":"2014","unstructured":"Wu X.H.; Ruan J.L.; Zhang J.; Wang S.Q.; Zhang Y.W.; Pallidifloside D, a saponin glycoside constituent from Smilax riparia, resist to hyperuricemia based on URAT1 and GLUT9 in hyperuricemic mice. J Ethnopharmacol  2014,157,201-205","journal-title":"J Ethnopharmacol"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.fitote.2015.06.002","volume":"105","author":"Hou P.Y.","year":"2015","unstructured":"Hou P.Y.; Mi C.; He Y.; Zhang J.; Wang S.Q.; Yu F.; Anderson S.; Zhang Y.W.; Wu X.H.; Pallidifloside D from Smilax riparia enhanced allopurinol effects in hyperuricemia mice. Fitoterapia  2015,105,43-48","journal-title":"Fitoterapia"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"102645","DOI":"10.1016\/j.bcab.2023.102645","volume":"48","author":"Endrini S.","year":"2023","unstructured":"Endrini S.; Abu Bakar F.I.; Abu Bakar M.F.; Abdullah N.; Marsiati H.; Phytochemical profiling, in vitro and in vivo xanthine oxidase inhibition and antihyperuricemic activity of Christia vespertilionis leaf. Biocatal Agric Biotechnol  2023,48,102645","journal-title":"Biocatal Agric Biotechnol"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"153850","DOI":"10.1016\/j.phymed.2021.153850","volume":"96","author":"Bao R.","year":"2022","unstructured":"Bao R.; Chen Q.; Li Z.; Wang D.; Wu Y.; Liu M.; Zhang Y.; Wang T.; Eurycomanol alleviates hyperuricemia by promoting uric acid excretion and reducing purine synthesis. Phytomedicine  2022,96,153850","journal-title":"Phytomedicine"},{"key":"ref=57","unstructured":"Nutraceutical on Hyperuricemia."},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"101723","DOI":"10.1016\/j.berh.2021.101723","volume":"35","author":"Danve A.","year":"2021","unstructured":"Danve A.; Sehra S.T.; Neogi T.; Role of diet in hyperuricemia and gout. Best Pract Res Clin Rheumatol  2021,35(4),101723","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"e0202901","DOI":"10.1371\/journal.pone.0202901","volume":"13","author":"Garc\u00eda-Arroyo F.E.","year":"2018","unstructured":"Garc\u00eda-Arroyo F.E.; Gonzaga G.; Mu\u00f1oz-Jim\u00e9nez I.; Blas-Marron M.G.; Silverio O.; Tapia E.; Soto V.; Ranganathan N.; Ranganathan P.; Vyas U.; Irvin A.; Ir D.; Robertson C.E.; Frank D.N.; Johnson R.J.; S\u00e1nchez-Lozada L.G.; Probiotic supplements prevented oxonic acid-induced hyperuricemia and renal damage. PLoS One  2018,13(8),e0202901","journal-title":"PLoS One"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"100416","DOI":"10.1016\/j.lanepe.2022.100416","volume":"18","author":"Russell M.D.","year":"2022","unstructured":"Russell M.D.; Rutherford A.I.; Ellis B.; Norton S.; Douiri A.; Gulliford M.C.; Cope A.P.; Galloway J.B.; Management of gout following 2016\/2017 European (EULAR) and British (BSR) guidelines: An interrupted time-series analysis in the United Kingdom. Lancet Reg Health Eur  2022,18,100416","journal-title":"Lancet Reg Health Eur"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.ijbiomac.2021.02.004","volume":"175","author":"Kim H.S.","year":"2021","unstructured":"Kim H.S.; Yun Y.H.; Shim W.G.; Yoon S.D.; Preparation and evaluation of functional allopurinol imprinted starch based biomaterials for transdermal drug delivery. Int J Biol Macromol  2021,175,217-228","journal-title":"Int J Biol Macromol"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"102859","DOI":"10.1016\/j.jddst.2021.102859","volume":"66","author":"Abdulaal W.H.","year":"2021","unstructured":"Abdulaal W.H.; Alhakamy N.A.; Hosny K.M.; Preparation and characterization of a thioctic acid nanostructured lipid carrier to enhance the absorption profile and limit the nephrotoxicity associated with allopurinol in the treatment of gout. J Drug Deliv Sci Technol  2021,66,102859","journal-title":"J Drug Deliv Sci Technol"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s40360-022-00625-y","volume":"23","author":"Ali Z.","year":"2022","unstructured":"Ali Z.; Din F.; Zahid F.; Sohail S.; Imran B.; Khan S.; Malik M.; Zeb A.; Khan G.M.; Transdermal delivery of allopurinol-loaded nanostructured lipid carrier in the treatment of gout. BMC Pharmacol Toxicol  2022,23(1),86","journal-title":"BMC Pharmacol Toxicol"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"224","DOI":"10.3390\/pharmaceutics15010224","volume":"15","author":"Patel B.","year":"2023","unstructured":"Patel B.; Thakkar H.; Formulation development of fast dissolving microneedles loaded with cubosomes of febuxostat: In vitro and in vivo evaluation. Pharmaceutics  2023,15(1),224","journal-title":"Pharmaceutics"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"61","DOI":"10.4274\/tjps.galenos.2019.32656","volume":"18","author":"Bhatt S.","year":"2021","unstructured":"Bhatt S.; Sharma J.B.; Kamboj R.; Kumar M.; Saini V.; Mandge S.; Design and optimization of febuxostat-loaded nano lipid carriers using full factorial design. Turk J Pharm Sci  2021,18(1),61-67","journal-title":"Turk J Pharm Sci"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.ijpharm.2014.12.003","volume":"478","author":"Ahuja B.K.","year":"2015","unstructured":"Ahuja B.K.; Jena S.K.; Paidi S.K.; Bagri S.; Suresh S.; Formulation, optimization and in vitro\u2013in vivo evaluation of febuxostat nanosuspension. Int J Pharm  2015,478(2),540-552","journal-title":"Int J Pharm"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1016\/j.molliq.2017.08.002","volume":"242","author":"Vohra A.M.","year":"2017","unstructured":"Vohra A.M.; Patel C.V.; Kumar P.; Thakkar H.P.; Development of dual drug loaded solid self microemulsifying drug delivery system: Exploring interfacial interactions using QbD coupled risk based approach. J Mol Liq  2017,242,1156-1168","journal-title":"J Mol Liq"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.powtec.2016.09.004","volume":"302","author":"Sharma O.P.","year":"2016","unstructured":"Sharma O.P.; Patel V.; Mehta T.; Design of experiment approach in development of febuxostat nanocrystal: Application of Soluplus as stabilizer. Powder Technol  2016,302,396-405","journal-title":"Powder Technol"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.jddst.2018.06.005","volume":"46","author":"Sheng X.","year":"2018","unstructured":"Sheng X.; Tang J.; Bao J.; Shi X.; Su W.; Enhancement of in vitro dissolution and in vivo performance\/oral absorption of FEB-poloxamer-TPGS solid dispersion. J Drug Deliv Sci Technol  2018,46,408-415","journal-title":"J Drug Deliv Sci Technol"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"534","DOI":"10.3390\/pharmaceutics12060534","volume":"12","author":"Al-Amodi Y.A.","year":"2020","unstructured":"Al-Amodi Y.A.; Hosny K.M.; Alharbi W.S.; Safo M.K.; El-Say K.M.; Investigating the potential of transmucosal delivery of febuxostat from oral lyophilized tablets loaded with a self-nanoemulsifying delivery system. Pharmaceutics  2020,12(6),534","journal-title":"Pharmaceutics"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1080\/10717544.2021.1927247","volume":"28","author":"Habib B.A.","year":"2021","unstructured":"Habib B.A.; Abd El-Samiae A.S.; El-Houssieny B.M.; Tag R.; Formulation, characterization, optimization, and in-vivo performance of febuxostat self-nano-emulsifying system loaded sublingual films. Drug Deliv  2021,28(1),1321-1333","journal-title":"Drug Deliv"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.jcis.2017.08.011","volume":"507","author":"Froelich A.","year":"2017","unstructured":"Froelich A.; Osma\u0142ek T.; Snela A.; Kunstman P.; Jadach B.; Olejniczak M.; Roszak G.; Bia\u0142as W.; Novel microemulsion-based gels for topical delivery of indomethacin: Formulation, physicochemical properties and in vitro drug release studies. J Colloid Interface Sci  2017,507,323-336","journal-title":"J Colloid Interface Sci"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.biomaterials.2006.07.046","volume":"28","author":"Chandrasekar D.","year":"2007","unstructured":"Chandrasekar D.; Sistla R.; Ahmad F.J.; Khar R.K.; Diwan P.V.; The development of folate-PAMAM dendrimer conjugates for targeted delivery of anti-arthritic drugs and their pharmacokinetics and biodistribution in arthritic rats. Biomaterials  2007,28(3),504-512","journal-title":"Biomaterials"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/j.ijbiomac.2021.03.033","volume":"180","author":"Salahuddin N.","year":"2021","unstructured":"Salahuddin N.; Gaber M.; Elneanaey S.; Snowdon M.R.; Abdelwahab M.A.; Co-delivery of norfloxacin and tenoxicam in Ag-TiO\/poly(lactic acid) nanohybrid. Int J Biol Macromol  2021,180,771-781","journal-title":"Int J Biol Macromol"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.ijpharm.2010.11.003","volume":"405","author":"Ammar H.O.","year":"2011","unstructured":"Ammar H.O.; Ghorab M.; El-Nahhas S.A.; Higazy I.M.; Proniosomes as a carrier system for transdermal delivery of tenoxicam. Int J Pharm  2011,405(1-2),142-152","journal-title":"Int J Pharm"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.molliq.2017.03.042","volume":"234","author":"Mahamat Nor S.B.","year":"2017","unstructured":"Mahamat Nor S.B.; Woi P.M.; Ng S.H.; Characterisation of ionic liquids nanoemulsion loaded with piroxicam for drug delivery system. J Mol Liq  2017,234,30-39","journal-title":"J Mol Liq"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.colsurfa.2011.12.017","volume":"395","author":"Liu M.","year":"2012","unstructured":"Liu M.; Chen L.; Zhao Y.; Gan L.; Zhu D.; Xiong W.; Lv Y.; Xu Z.; Hao Z.; Chen L.; Preparation, characterization and properties of liposome-loaded polycaprolactone microspheres as a drug delivery system. Colloids Surf A Physicochem Eng Asp  2012,395,131-136","journal-title":"Colloids Surf A Physicochem Eng Asp"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1111\/bjd.15896","volume":"178","author":"Dasgeb B.","year":"2018","unstructured":"Dasgeb B.; Kornreich D.; McGuinn K.; Okon L.; Brownell I.; Sackett D.L.; Colchicine: An ancient drug with novel applications. Br J Dermatol  2018,178(2),350-356","journal-title":"Br J Dermatol"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"46","DOI":"10.3390\/molecules25010046","volume":"25","author":"Zoghebi K.A.","year":"2019","unstructured":"Zoghebi K.A.; Bousoik E.; Parang K.; Elsaid K.A.; Design and biological evaluation of colchicine-CD44-targeted peptide conjugate in an in vitro model of crystal induced inflammation. Molecules  2019,25(1),46","journal-title":"Molecules"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"124381","DOI":"10.1016\/j.matchemphys.2021.124381","volume":"263","author":"Morad H.","year":"2021","unstructured":"Morad H.; Jahanshahi M.; Akbari J.; Saeedi M.; Gill P.; Enayatifard R.; Novel topical and transdermal delivery of colchicine with chitosan based biocomposite nanofiberous system; formulation, optimization, characterization, ex vivo skin deposition\/permeation, and anti-melanoma evaluation. Mater Chem Phys  2021,263(263),124381","journal-title":"Mater Chem Phys"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.jddst.2018.10.036","volume":"49","author":"El-Feky G.S.","year":"2019","unstructured":"El-Feky G.S.; El-Naa M.M.; Mahmoud A.A.; Flexible nano-sized lipid vesicles for the transdermal delivery of colchicine; in vitro\/in vivo investigation. J Drug Deliv Sci Technol  2019,49(49),24-34","journal-title":"J Drug Deliv Sci Technol"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"103051","DOI":"10.1016\/j.jddst.2021.103051","volume":"67","author":"Lv B.","year":"2022","unstructured":"Lv B.; Yang G.; Wei Y.; Lei Y.; Ding Y.; Gong W.; Wang Y.; Gao C.; Han C.; A pharmacokinetic and pharmacodynamic evaluation of colchicine sustained-release pellets for preventing gout. J Drug Deliv Sci Technol  2022,67(67),103051","journal-title":"J Drug Deliv Sci Technol"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"100698","DOI":"10.1016\/j.coco.2021.100698","volume":"25","author":"Zeng Z.","year":"2021","unstructured":"Zeng Z.; Feng H.; Hao M.; Zhang Y.; One-pot approach to form in situ colchicine-containing nano-hydroxyapatite within microemulsion composite system for sustained transdermal delivery. Compos Commun  2021,25(February),100698","journal-title":"Compos Commun"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1080\/10717544.2018.1559258","volume":"26","author":"Zhang Y.","year":"2019","unstructured":"Zhang Y.; Zhang N.; Song H.; Li H.; Wen J.; Tan X.; Zheng W.; Design, characterization and comparison of transdermal delivery of colchicine via borneol-chemically-modified and borneol-physically-modified ethosome. Drug Deliv  2019,26(1),70-77","journal-title":"Drug Deliv"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"795","DOI":"10.2147\/DDDT.S158018","volume":"12","author":"Abdulbaqi I.M.","year":"2018","unstructured":"Abdulbaqi I.M.; Darwis Y.; Abou Assi R.; Abdul Karim Khan N.; Transethosomal gels as carriers for the transdermal delivery of colchicine: statistical optimization, characterization, and ex vivo evaluation. Drug Des Devel Ther  2018,12,795-813","journal-title":"Drug Des Devel Ther"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"2984","DOI":"10.1080\/10717544.2022.2122632","volume":"29","author":"Liu Y.","year":"2022","unstructured":"Liu Y.; Zhu X.; Ji S.; Huang Z.; Zang Y.; Ding Y.; Zhang J.; Ding Z.; Transdermal delivery of colchicine using dissolvable microneedle arrays for the treatment of acute gout in a rat model. Drug Deliv  2022,29(1),2984-2994","journal-title":"Drug Deliv"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.3390\/pharmaceutics14102245","volume":"14","author":"Lei Y.","year":"2022","unstructured":"Lei Y.; Yang G.; Du F.; Yi J.; Quan L.; Liu H.; Zhou X.; Gong W.; Han J.; Wang Y.; Gao C.; Formulation and evaluation of a drug-in-adhesive patch for transdermal delivery of colchicine. Pharmaceutics  2022,14(10),2245","journal-title":"Pharmaceutics"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"110642","DOI":"10.1016\/j.matdes.2022.110642","volume":"217","author":"Sun J.","year":"2022","unstructured":"Sun J.; Zhuang P.; Wen S.; Ge M.; Zhou Z.; Li D.; Liu C.; Mei X.; Folic acid-modified lysozyme protected gold nanoclusters as an effective anti-inflammatory drug for rapid relief of gout flares in hyperuricemic rats. Mater Des  2022,217,110642","journal-title":"Mater Des"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1016\/j.jconrel.2020.05.037","volume":"324","author":"Cho J.","year":"2020","unstructured":"Cho J.; Kim S.H.; Yang B.; Jung J.M.; Kwon I.; Lee D.S.; Albumin affibody-outfitted injectable gel enabling extended release of urate oxidase-albumin conjugates for hyperuricemia treatment. J Control Release  2020,324,532-544","journal-title":"J Control Release"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.jconrel.2017.03.019","volume":"255","author":"Zhang X.","year":"2017","unstructured":"Zhang X.; Xu D.; Jin X.; Liu G.; Liang S.; Wang H.; Chen W.; Zhu X.; Lu Y.; Nanocapsules of therapeutic proteins with enhanced stability and long blood circulation for hyperuricemia management. J Control Release  2017,255,54-61","journal-title":"J Control Release"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.jconrel.2019.07.038","volume":"309","author":"Kim S.","year":"2019","unstructured":"Kim S.; Kim M.; Jung S.; Kwon K.; Park J.; Kim S.; Kwon I.; Tae G.; Co-delivery of therapeutic protein and catalase-mimic nanoparticle using a biocompatible nanocarrier for enhanced therapeutic effect. J Control Release  2019,309,181-189","journal-title":"J Control Release"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1021\/acs.biomac.2c01388","volume":"24","author":"Tran L.","year":"2023","unstructured":"Tran L.; Das S.; Zhao L.; Finn M.G.; Gaucher E.A.; Oral delivery of nanoparticles carrying ancestral uricase enzyme protects against hyperuricemia in knockout mice. Biomacromolecules  2023,24(5),2003-2008","journal-title":"Biomacromolecules"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1166\/jbn.2019.2752","volume":"15","author":"Hao Y.","year":"2019","unstructured":"Hao Y.; Li H.; Cao Y.; Chen Y.; Lei M.; Zhang T.; Xiao Y.; Chu B.; Qian Z.; Uricase and horseradish peroxidase hybrid CaHPO nanoflower integrated with transcutaneous patches for treatment of hyperuricemia. J Biomed Nanotechnol  2019,15(5),951-965","journal-title":"J Biomed Nanotechnol"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.jtemb.2019.08.012","volume":"56","author":"Kiyani M.M.","year":"2019","unstructured":"Kiyani M.M.; Butt M.A.; Rehman H.; Ali H.; Hussain S.A.; Obaid S.; Arif Hussain M.; Mahmood T.; Bokhari S.A.I.; Antioxidant and anti-gout effects of orally administered zinc oxide nanoparticles in gouty mice. J Trace Elem Med Biol  2019,56,169-177","journal-title":"J Trace Elem Med Biol"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.ijpharm.2018.08.028","volume":"550","author":"Wang Q.","year":"2018","unstructured":"Wang Q.; Yang Q.; Cao X.; Wei Q.; Firempong C.K.; Guo M.; Shi F.; Xu X.; Deng W.; Yu J.; Enhanced oral bioavailability and anti-gout activity of [6]-shogaol-loaded solid lipid nanoparticles. Int J Pharm  2018,550(1-2),24-34","journal-title":"Int J Pharm"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"118735","DOI":"10.1016\/j.ijpharm.2019.118735","volume":"572","author":"Weng W.","year":"2019","unstructured":"Weng W.; Wang Q.; Wei C.; Man N.; Zhang K.; Wei Q.; Adu-Frimpong M.; Toreniyazov E.; Ji H.; Yu J.; Xu X.; Preparation, characterization, pharmacokinetics and anti-hyperuricemia activity studies of myricitrin-loaded proliposomes. Int J Pharm  2019,572,118735","journal-title":"Int J Pharm"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"4152","DOI":"10.3390\/molecules24224152","volume":"24","author":"Wang X.","year":"2019","unstructured":"Wang X.; Zhang Y.; Zhang M.; Kong H.; Wang S.; Cheng J.; Qu H.; Zhao Y.; Novel carbon dots derived from Puerariae lobatae radix and their anti-gout effects. Molecules  2019,24(22),4152","journal-title":"Molecules"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"101487","DOI":"10.1016\/j.jddst.2019.101487","volume":"55","author":"Chen Z.","year":"2020","unstructured":"Chen Z.; Han B.; Liao L.; Hu X.; Hu Q.; Gao Y.; Qiu Y.; Enhanced transdermal delivery of polydatin via a combination of inclusion complexes and dissolving microneedles for treatment of acute gout arthritis. J Drug Deliv Sci Technol  2020,55(55),101487","journal-title":"J Drug Deliv Sci Technol"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"303","DOI":"10.18502\/ajmb.v14i4.10485","volume":"14","author":"Karunakaran S.","year":"2022","unstructured":"Karunakaran S.; Hari R.; Comparative antioxidant and anti-gout activities of Citrullus colocynthis loaded fruit silver nanoparticles with its ethanolic extract. Avicenna J Med Biotechnol  2022,14(4),303-309","journal-title":"Avicenna J Med Biotechnol"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"102810","DOI":"10.1016\/j.jddst.2021.102810","volume":"66","author":"Xu W.","year":"2021","unstructured":"Xu W.; Liang M.; Su W.; Yang J.; Pu F.; Xie Z.; Jin K.; Polyakov N.E.; Dushkin A.V.; Su W.; Self-assembled nanocapsules of celery (Apium graveolens Linn) seed oil: Mechanochemical preparation, characterization and urate-lowering activity. J Drug Deliv Sci Technol  2021,66,102810","journal-title":"J Drug Deliv Sci Technol"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"137","DOI":"10.34172\/apb.2021.015","volume":"11","author":"Valsalan Soba S.","year":"2020","unstructured":"Valsalan Soba S.; Babu M.; Panonnummal R.; Ethosomal gel formulation of alpha phellandrene for the transdermal delivery in gout. Adv Pharm Bull  2020,11(1),137-149","journal-title":"Adv Pharm Bull"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"109195","DOI":"10.1016\/j.biopha.2019.109195","volume":"118","author":"Chen Y.","year":"2019","unstructured":"Chen Y.; Li C.; Duan S.; Yuan X.; Liang J.; Hou S.; Curcumin attenuates potassium oxonate-induced hyperuricemia and kidney inflammation in mice. Biomed Pharmacother  2019,118,109195","journal-title":"Biomed Pharmacother"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3390\/medicina55010010","volume":"55","author":"Mustafa Kiyani M.M.","year":"2019","unstructured":"Mustafa Kiyani M.M.; Sohail M.F.; Shahnaz G.; Rehman H.; Akhtar M.F.; Nawaz I.; Mahmood T.; Manzoor M.; Imran Bokhari S.A.; Evaluation of turmeric nanoparticles as anti-gout agent: Modernization of a traditional drug. Medicina  2019,55(1),10","journal-title":"Medicina"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1007\/s13205-015-0302-9","volume":"5","author":"Pandit R.S.","year":"2015","unstructured":"Pandit R.S.; Gaikwad S.C.; Agarkar G.A.; Gade A.K.; Rai M.; Curcumin nanoparticles: Physico-chemical fabrication and its in vitro efficacy against human pathogens. 3 Biotech  2015,5(6),991-997","journal-title":"3 Biotech"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.bioactmat.2021.06.003","volume":"8","author":"Zhang M.","year":"2022","unstructured":"Zhang M.; Zhang X.; Tian T.; Zhang Q.; Wen Y.; Zhu J.; Xiao D.; Cui W.; Lin Y.; Anti-inflammatory activity of curcumin-loaded tetrahedral framework nucleic acids on acute gouty arthritis. Bioact Mater  2022,8,368-380","journal-title":"Bioact Mater"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1016\/j.nano.2016.02.010","volume":"12","author":"Xiong H.","year":"2016","unstructured":"Xiong H.; Zhou Y.; Zhou Q.; He D.; Deng X.; Sun Q.; Zhang J.; Nanocapsule assemblies as effective enzyme delivery systems against hyperuricemia. Nanomedicine  2016,12(6),1557-1566","journal-title":"Nanomedicine"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"13979","DOI":"10.1038\/s41598-018-32334-0","volume":"8","author":"Ruiz-Miyazawa K.W.","year":"2018","unstructured":"Ruiz-Miyazawa K.W.; Staurengo-Ferrari L.; Pinho-Ribeiro F.A.; Fattori V.; Zaninelli T.H.; Badaro-Garcia S.; Borghi S.M.; Andrade K.C.; Clemente-Napimoga J.T.; Alves-Filho J.C.; Cunha T.M.; Fraceto L.F.; Cunha F.Q.; Napimoga M.H.; Casagrande R.; Verri W.A.; 15d-PGJ-loaded nanocapsules ameliorate experimental gout arthritis by reducing pain and inflammation in a PPAR-gamma-sensitive manner in mice. Sci Rep  2018,8(1),13979","journal-title":"Sci Rep"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"484","DOI":"10.3390\/pharmaceutics15020484","volume":"15","author":"Lou J.","year":"2023","unstructured":"Lou J.; Duan H.; Qin Q.; Teng Z.; Gan F.; Zhou X.; Zhou X.; Advances in oral drug delivery systems: Challenges and opportunities. Pharmaceutics  2023,15(2),484","journal-title":"Pharmaceutics"},{"key":"ref=109","doi-asserted-by":"publisher","DOI":"10.2174\/1389201021666200804155535","volume":"21","author":"\u00dcst\u00fcnda\u011f Okur N.","year":"2020","unstructured":"\u00dcst\u00fcnda\u011f Okur N.; Siafaka P.I.; G\u00f6k\u00e7e E.H.; Challenges in oral drug delivery and applications of lipid nanoparticles as potent oral drug carriers for managing cardiovascular risk factors. Curr Pharm Biotechnol  2020,21","journal-title":"Curr Pharm Biotechnol"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/S1773-2247(14)50041-X","volume":"24","author":"Ita K.B.","year":"2014","unstructured":"Ita K.B.; Transdermal drug delivery: Progress and challenges. J Drug Deliv Sci Technol  2014,24(3),245-250","journal-title":"J Drug Deliv Sci Technol"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s12891-023-06186-3","volume":"24","author":"Zhu R.","year":"2023","unstructured":"Zhu R.; Niu Y.; Zhou W.; Wang S.; Mao J.; Guo Y.; Lei Y.; Xiong X.; Li Y.; Guo L.; Effect of nanoparticles on gouty arthritis: A systematic review and meta-analysis. BMC Musculoskelet Disord  2023,24(1),124","journal-title":"BMC Musculoskelet Disord"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s40744-020-00222-7","volume":"7","author":"Albert J.A.","year":"2020","unstructured":"Albert J.A.; Hosey T.; LaMoreaux B.; Increased efficacy and tolerability of pegloticase in patients with uncontrolled gout co-treated with methotrexate: A retrospective study. Rheumatol Ther  2020,7(3),639-648","journal-title":"Rheumatol Ther"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1016\/S0140-6736(08)60799-0","volume":"371","author":"Janssens H.J.E.M.","year":"2008","unstructured":"Janssens H.J.E.M.; Janssen M.; van de Lisdonk E.H.; van Riel P.L.C.M.; van Weel C.; Use of oral prednisolone or naproxen for the treatment of gout arthritis: A double-blind, randomised equivalence trial. Lancet  2008,371(9627),1854-1860","journal-title":"Lancet"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"83","DOI":"10.7150\/ijms.4.83","volume":"4","author":"Cammalleri L.","year":"2007","unstructured":"Cammalleri L.; Malaguarnera M.; Rasburicase represents a new tool for hyperuricemia in tumor lysis syndrome and in gout. Int J Med Sci  2007,4(2),83-93","journal-title":"Int J Med Sci"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"1650.1","DOI":"10.1136\/annrheumdis-2022-eular.3450","volume":"81","author":"Zeng W.C.","year":"2022","unstructured":"Zeng W.C.; Li Q.H.; Tang A.J.; Li H.G.; Chen L.F.; Wei X.N.; Liang J.J.; Zheng D.H.; Dai L.; Mo Y.Q.; AB1057 efficacy and safety of low-dose rasburicase in combination with conventional urate-lowering therapy for refractory chronic gouty arthritis: A pilot study in. Ann Rheum Dis  2022,81(S1),1650.1-1650","journal-title":"Ann Rheum Dis"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"","DOI":"10.1136\/annrheumdis-2018-eular.3962","author":"Ivanov D.D.","year":"2018","unstructured":"Ivanov D.D.; Sinjchenko O.V.; Golovach I.Y.; Bevzenko T.B.; Ivanova M.D.;  THU0687 The Impact of Urate-Lowering Therapy on Kidney Function (IMPULSKF): Preliminary Results  2018,-537","journal-title":"THU0687 The Impact of Urate-Lowering Therapy on Kidney Function (IMPULSKF): Preliminary Results"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1002\/art.42447","volume":"75","author":"Terkeltaub R.","year":"2023","unstructured":"Terkeltaub R.; Lee J.; Min J.; Shin S.; Saag K.G.; Serum urate\u2013lowering efficacy and safety of tigulixostat in gout patients with hyperuricemia: A randomized, double-blind, placebo-controlled, dose-finding trial. Arthritis Rheumatol  2023,75(7),1275-1284","journal-title":"Arthritis Rheumatol"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"e14674","DOI":"10.1111\/ijcp.14674","volume":"75","author":"Noori S.","year":"2021","unstructured":"Noori S.; Mirzababaei A.; Amini M.R.; Clark C.C.T.; Mirzaei K.; Effect of orlistat on serum uric acid level in adults: A systematic review and meta-analysis of randomised controlled trials. Int J Clin Pract  2021,75(11),e14674","journal-title":"Int J Clin Pract"},{"key":"ref=119","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X211067304","author":"Tang H.","year":"2022","unstructured":"Tang H.; Cui B.; Chen Y.; Chen L.; Wang Z.; Zhang N.; Yang Y.; Wang X.; Xie X.; Sun L.; Dang W.; Wang X.; Li R.; Zou J.; Zhao Y.; Liu Y.; Safety and efficacy of SHR4640 combined with febuxostat for primary hyperuricemia: A multicenter, randomized, double-blind, phase II study. Ther Adv Musculoskelet Dis  2022","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"907.1","DOI":"10.1136\/annrheumdis-2022-eular.1662","volume":"81","author":"Terkeltaub R.","year":"2022","unstructured":"Terkeltaub R.; Clark D.; Tosone C.; Kandinov B.; Zhang P.; Dahl N.; Grujic D.; Goldfarb D.; POS1157 safety and efficacy of alln-346 oral enzyme therapy in patients with hyperuricemia and chronic kidney disease (CKD): Results of the phase 2a study 201. Ann Rheum Dis  2022,81(907),907.1-907","journal-title":"Ann Rheum Dis"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"e270","DOI":"10.1016\/S2665-9913(20)30065-5","volume":"2","author":"Kl\u00fcck V.","year":"2020","unstructured":"Kl\u00fcck V.; Jansen T.L.T.A.; Janssen M.; Comarniceanu A.; Efd\u00e9 M.; Tengesdal I.W.; Schraa K.; Cleophas M.C.P.; Scribner C.L.; Skouras D.B.; Marchetti C.; Dinarello C.A.; Joosten L.A.B.; Dapansutrile, an oral selective NLRP3 inflammasome inhibitor, for treatment of gout flares: an open-label, dose-adaptive, proof-of-concept, phase 2a trial. Lancet Rheumatol  2020,2(5),e270-e280","journal-title":"Lancet Rheumatol"}],"container-title":["Current Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0929867331666230809143758","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/219592\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0929867331666230809143758","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,20]],"date-time":"2024-10-20T14:02:32Z","timestamp":1729432952000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/219592\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":121,"journal-issue":{"issue":"36","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0929867331666230809143758","relation":{},"ISSN":["0929-8673"],"issn-type":[{"value":"0929-8673","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2023-04-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-24","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}